Biotron (BIT) Stock Price, News & Analysis

Company Overview

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.03 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 5.08%
• Price Target: N/A
• Consensus Rating: N/A

BIT Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Biotron own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotron investors own include TPG Co. Limited (TPM.AX) (TPM), Gemfields Group (GEM), Northern Star Resources (NST), Nokia Oyj (NOK), Mesoblast (MESO), MARA (MARA) and FYI Resources (FYI).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:BIT
• CUSIP: N/A
• CIK: N/A
• Web: www.biotron.com.au
• Phone: 61 2 9805 0488
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,440,000.00
• Net Margins: -208.89%
• Pretax Margin: N/A
• Return on Equity: -234.68%
• Return on Assets: -94.68%

Debt

• Debt-to-Equity Ratio: 1.50
• Current Ratio: 0.58
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: $1.65 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 6.71
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 902,310,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.61